AT&T Inc. (NYSE: T) is in discussions with multiple companies to sell its subsidiary Warner Bros. Interactive Entertainment, according to a CNBC report Friday.What Happened Multiple companies, including Electronic Arts Inc. (NASDAQ: EA), Activision Blizzard, Inc. (NASDAQ: ATVI), and Take-Two Interactive Software Inc. (NASDAQ: TTWO), have expressed interest in purchasing the video game unit, CNBC reported.A deal, if finalized, could fetch AT&T as much as $4 billion, according to CNBC. The Dallas conglomerate had acquired Times Warner, of which the gaming division is a part, for about $109 billion in 2018.CNBC learned that AT&T is likely to strike a deal where it continues to receive compensation for intellectual property from the games even after the unit is sold. Some of the major Warner video games are based on AT&T-owned franchises like Harry Potter, Game of Thrones, and The Lego Movie.Why It Matters It isn't immediately clear why AT&T is looking to sell the gaming unit. Activist investment firm Elliott Management Corp. revealed a .2 billion stake in the telecommunication giant in September last year and has since pushed for divestment in non-core holdings, including DirecTV.AT&T last month raised $12.5 billion in a debt offering, as reported by Bloomberg.AT&T Price Action AT&T shares closed nearly 1.1% higher at $30.5 on Friday and inched slightly higher in the after-hours session.See more from Benzinga * US Debt Market Raised .5B This Week, The Highest Since 2007: FT(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

from Yahoo Finance https://ift.tt/30K14yU

Dr Reddy's Laboratories Ltd. (RDY) announced that it has entered into a non-exclusive licensing agreement to manufacture and sell Gilead Sciences Inc.’s (GILD) coronavirus drug candidate remdesivir.The agreement grants Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug remdesivir, a potential treatment for COVID-19, in 127 countries including India. Financial terms of the agreement weren’t disclosed.As part of the pact, Gilead will provide technology transfer for the manufacturing of the potential drug. However, Dr. Reddy’s will be in charge of ramping up manufacturing and obtaining regulatory approval for the marketing of remdesivir in respective countries.Gilead’s investigational antiviral therapy has received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat Covid-19.Shares in Gilead have dropped about 5% over the past week and were trading at $73.20 as of Friday’s close.Five-star analyst Hartaj Singh at Oppenheimer last week reiterated his Buy rating on the stock with a $90 price target (23% upside potential), saying that investors are ascribing little value to Gilead's quality emerging pipeline, and that any sustained weakness into 2Q20 should be viewed as a buying opportunity.Singh noted that although the stock has this year outperformed the broader market and its peer-group indices, the trend has reversed over the past month. He attributes three reasons for this: a rotation from biotech into other sectors, concerns around monetizing remdesivir's potential in COVID-19 and a tricky 2Q20 earnings report coming up in late July.The analyst added that Gilead’s $1 billion investment in remdesivir manufacturing, R&D and sales and marketing efforts are potentially not reflected in 2Q/3Q20 consensus earnings estimates, which could potentially lead to earnings misses.So what does the Street consensus say? TipRanks data shows that the majority of 14 analysts have a Hold rating on the stock, while the rest is divided between 10 Buys and 4 Sells, adding up to a Hold consensus. The $79.95 average price target  is less optimistic than Singh’s as it indicates 9% upside potential in the shares in the coming 12 months. (See Gilead stock analysis on TipRanks).Related News: Israel Is Said To Be In Talks To Buy Moderna’s Covid-19 Vaccine Candidate 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed AstraZeneca Inks Europe Deal For 400M Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Tesla’s China Car Registrations Jump In May; Stock Down In Pre-Market On Analysts’ Rating Cuts * Accenture To Snap Up Sentelis In Latest AI-Boosting Move * Unilever To Invest €1 Billion In 10-Year Climate And Nature Fund * RBC Slashes Cineplex Outlook As Major C$2.8B Deal Terminated

from Yahoo Finance https://ift.tt/2Y4sCxn

from Yahoo Finance https://ift.tt/2MWE5ss